79 related articles for article (PubMed ID: 19938904)
1. Brostallicin (PNU-166196), a new minor groove DNA binder: preclinical and clinical activity.
Lorusso D; Mainenti S; Pietragalla A; Ferrandina G; Foco G; Masciullo V; Scambia G
Expert Opin Investig Drugs; 2009 Dec; 18(12):1939-46. PubMed ID: 19938904
[TBL] [Abstract][Full Text] [Related]
2. Brostallicin, a novel anticancer agent whose activity is enhanced upon binding to glutathione.
Geroni C; Marchini S; Cozzi P; Galliera E; Ragg E; Colombo T; Battaglia R; Howard M; D'Incalci M; Broggini M
Cancer Res; 2002 Apr; 62(8):2332-6. PubMed ID: 11956092
[TBL] [Abstract][Full Text] [Related]
3. Enhancement of in vivo antitumor activity of classical anticancer agents by combination with the new, glutathione-interacting DNA minor groove-binder, brostallicin.
Sabatino MA; Colombo T; Geroni C; Marchini S; Broggini M
Clin Cancer Res; 2003 Nov; 9(14):5402-8. PubMed ID: 14614026
[TBL] [Abstract][Full Text] [Related]
4. Phase I dose-escalation study of brostallicin, a minor groove binder, in combination with cisplatin in patients with advanced solid tumors.
Caponigro F; Lorusso D; Fornari G; Barone C; Merlano M; Airoldi M; Schena M; MacArthur R; Weitman S; Jannuzzo MG; Crippa S; Fiorentini F; Petroccione A; Comis S
Cancer Chemother Pharmacol; 2010 Jul; 66(2):389-94. PubMed ID: 20480279
[TBL] [Abstract][Full Text] [Related]
5. Cytotoxic alpha-halogenoacrylic derivatives of distamycin A and congeners.
Beria I; Baraldi PG; Cozzi P; Caldarelli M; Geroni C; Marchini S; Mongelli N; Romagnoli R
J Med Chem; 2004 May; 47(10):2611-23. PubMed ID: 15115402
[TBL] [Abstract][Full Text] [Related]
6. Phase I and pharmacokinetic study of brostallicin (PNU-166196), a new DNA minor-groove binder, administered intravenously every 3 weeks to adult patients with metastatic cancer.
Ten Tije AJ; Verweij J; Sparreboom A; Van Der Gaast A; Fowst C; Fiorentini F; Tursi J; Antonellini A; Mantel M; Hartman CM; Stoter G; Planting AS; De Jonge MJ
Clin Cancer Res; 2003 Aug; 9(8):2957-64. PubMed ID: 12912942
[TBL] [Abstract][Full Text] [Related]
7. Brostallicin versus doxorubicin as first-line chemotherapy in patients with advanced or metastatic soft tissue sarcoma: an European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group randomised phase II and pharmacogenetic study.
Gelderblom H; Blay JY; Seddon BM; Leahy M; Ray-Coquard I; Sleijfer S; Kerst JM; Rutkowski P; Bauer S; Ouali M; Marreaud S; van der Straaten RJ; Guchelaar HJ; Weitman SD; Hogendoorn PC; Hohenberger P
Eur J Cancer; 2014 Jan; 50(2):388-96. PubMed ID: 24215845
[TBL] [Abstract][Full Text] [Related]
8. Zebularine partially reverses GST methylation in prostate cancer cells and restores sensitivity to the DNA minor groove binder brostallicin.
Sabatino MA; Geroni C; Ganzinelli M; Ceruti R; Broggini M
Epigenetics; 2013 Jun; 8(6):656-65. PubMed ID: 23771052
[TBL] [Abstract][Full Text] [Related]
9. Role of glutathione transferases in the mechanism of brostallicin activation.
Pezzola S; Antonini G; Geroni C; Beria I; Colombo M; Broggini M; Marchini S; Mongelli N; Leboffe L; MacArthur R; Mozzi AF; Federici G; Caccuri AM
Biochemistry; 2010 Jan; 49(1):226-35. PubMed ID: 19950984
[TBL] [Abstract][Full Text] [Related]
10. Potent antitumor activity of MS-247, a novel DNA minor groove binder, evaluated by an in vitro and in vivo human cancer cell line panel.
Yamori T; Matsunaga A; Sato S; Yamazaki K; Komi A; Ishizu K; Mita I; Edatsugi H; Matsuba Y; Takezawa K; Nakanishi O; Kohno H; Nakajima Y; Komatsu H; Andoh T; Tsuruo T
Cancer Res; 1999 Aug; 59(16):4042-9. PubMed ID: 10463605
[TBL] [Abstract][Full Text] [Related]
11. Brostallicin: a new concept in minor groove DNA binder development.
Broggini M; Marchini S; Fontana E; Moneta D; Fowst C; Geroni C
Anticancer Drugs; 2004 Jan; 15(1):1-6. PubMed ID: 15090736
[TBL] [Abstract][Full Text] [Related]
12. A phase I dose-escalation and pharmacokinetic study of brostallicin (PNU-166196A), a novel DNA minor groove binder, in adult patients with advanced solid tumors.
Lockhart AC; Howard M; Hande KR; Roth BJ; Berlin JD; Vreeland F; Campbell A; Fontana E; Fiorentini F; Fowst C; Paty VA; Lankford O; Rothenberg ML
Clin Cancer Res; 2004 Jan; 10(2):468-75. PubMed ID: 14760067
[TBL] [Abstract][Full Text] [Related]
13. The discovery of a new potential anticancer drug: a case history.
Cozzi P
Farmaco; 2003 Mar; 58(3):213-20. PubMed ID: 12620417
[TBL] [Abstract][Full Text] [Related]
14. Brostallicin (PNU-166196)--a new DNA minor groove binder that retains sensitivity in DNA mismatch repair-deficient tumour cells.
Fedier A; Fowst C; Tursi J; Geroni C; Haller U; Marchini S; Fink D
Br J Cancer; 2003 Oct; 89(8):1559-65. PubMed ID: 14562032
[TBL] [Abstract][Full Text] [Related]
15. Induction of glutathione-dependent DNA double-strand breaks by the novel anticancer drug brostallicin.
Guirouilh-Barbat J; Zhang YW; Pommier Y
Mol Cancer Ther; 2009 Jul; 8(7):1985-94. PubMed ID: 19584235
[TBL] [Abstract][Full Text] [Related]
16. Ifosfamide-based drug combinations: preclinical evaluation of drug interactions and translation into the clinic.
Vanhoefer U; Schleucher N; Klaassen U; Seeber S; Harstrick A
Semin Oncol; 2000 Feb; 27(1 Suppl 1):8-13. PubMed ID: 10697038
[TBL] [Abstract][Full Text] [Related]
17. SJG-136 (NSC 694501), a novel rationally designed DNA minor groove interstrand cross-linking agent with potent and broad spectrum antitumor activity: part 1: cellular pharmacology, in vitro and initial in vivo antitumor activity.
Hartley JA; Spanswick VJ; Brooks N; Clingen PH; McHugh PJ; Hochhauser D; Pedley RB; Kelland LR; Alley MC; Schultz R; Hollingshead MG; Schweikart KM; Tomaszewski JE; Sausville EA; Gregson SJ; Howard PW; Thurston DE
Cancer Res; 2004 Sep; 64(18):6693-9. PubMed ID: 15374986
[TBL] [Abstract][Full Text] [Related]
18. Combination of thiol antioxidant Silibinin with Brostallicin is associated with increase in the anti-apoptotic protein Bcl-2 and decrease in caspase 3 activity.
Pook SH; Toh CK; Mahendran R
Cancer Lett; 2006 Jul; 238(1):146-52. PubMed ID: 16111802
[TBL] [Abstract][Full Text] [Related]
19. Brostallicin, an agent with potential activity in metastatic soft tissue sarcoma: a phase II study from the European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group.
Leahy M; Ray-Coquard I; Verweij J; Le Cesne A; Duffaud F; Hogendoorn PC; Fowst C; de Balincourt C; di Paola ED; van Glabbeke M; Judson I; Blay JY;
Eur J Cancer; 2007 Jan; 43(2):308-15. PubMed ID: 17095209
[TBL] [Abstract][Full Text] [Related]
20. Antitumor activity of imidazothioxanthones in murine and human tumor models in vitro and in vivo.
Varvaresou A; Iakovou K; Gikas E; Fichtner I; Fiebig HH; Kelland LR; Double JA; Bibby MC; Hendriks HR
Anticancer Res; 2004; 24(2B):907-19. PubMed ID: 15161044
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]